Literature DB >> 23615773

Positively charged polymeric nanoparticle reservoirs of terbinafine hydrochloride: preclinical implications for controlled drug delivery in the aqueous humor of rabbits.

Saadia Ahmed Tayel1, Mohamed Ahmed El-Nabarawi, Mina Ibrahim Tadros, Wessam Hamdy Abd-Elsalam.   

Abstract

Frequent instillation of terbinafine hydrochloride (T HCl) eye drops (0.25%, w/v) is necessary to maintain effective aqueous humor concentrations for treatment of fungal keratitis. The current approach aimed at developing potential positively charged controlled-release polymeric nanoparticles (NPs) of T HCl. The estimation of the drug pharmacokinetics in the aqueous humor following ocular instillation of the best-achieved NPs in rabbits was another goal. Eighteen drug-loaded (0.50%, w/v) formulae were fabricated by the nanopreciptation method using Eudragit® RS100 and chitosan (0.25%, 0.5%, and 1%, w/v). Soybean lecithin (1%, w/v) and Pluronic® F68 (0.5%, 1%, and 1.5%, w/v) were incorporated in the alcoholic and aqueous phases, respectively. The NPs were evaluated for particle size, zeta potential, entrapment efficiency percentage (EE%), morphological examination, drug release in simulated tear fluid (pH 7.4), Fourier-transform IR (FT-IR), X-ray diffraction (XRD), physical stability (2 months, 4°C and 25°C), and drug pharmacokinetics in the rabbit aqueous humor relative to an oily drug solution. Spherical, discrete NPs were successfully developed with mean particle size and zeta potential ranging from 73.29 to 320.15 nm and +20.51 to +40.32 mV, respectively. Higher EE% were achieved with Eudragit® RS100-based NPs. The duration of drug release was extended to more than 8 h. FT-IR and XRD revealed compatibility between inactive formulation ingredients and T HCl and permanence of the latter's crystallinity, respectively. The NPs were physically stable, for at least 2 months, when refrigerated. F5-NP suspension significantly (P<0.05) increased drug mean residence time and improved its ocular bioavailability; 1.657-fold.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23615773      PMCID: PMC3665996          DOI: 10.1208/s12249-013-9964-y

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  40 in total

1.  Moxifloxacin-Gelrite in situ ophthalmic gelling system against photodynamic therapy for treatment of bacterial corneal inflammation.

Authors:  Hanan M El-Laithy; Demiana I Nesseem; Amira A El-Adly; Meriana Shoukry
Journal:  Arch Pharm Res       Date:  2011-11-12       Impact factor: 4.946

2.  Mucoadhesive nanoparticles for prolonged ocular delivery of natamycin: In vitro and pharmacokinetics studies.

Authors:  R S Bhatta; H Chandasana; Y S Chhonker; C Rathi; D Kumar; K Mitra; P K Shukla
Journal:  Int J Pharm       Date:  2012-04-28       Impact factor: 5.875

Review 3.  Chitosan-based nanostructures: a delivery platform for ocular therapeutics.

Authors:  Maria de la Fuente; Manuela Raviña; Patrizia Paolicelli; Alejandro Sanchez; Begoña Seijo; Maria Jose Alonso
Journal:  Adv Drug Deliv Rev       Date:  2009-12-01       Impact factor: 15.470

4.  Fleroxacin pharmacokinetics in aqueous and vitreous humors determined by using complete concentration-time data from individual rabbits.

Authors:  M H Miller; A Madu; G Samathanam; D Rush; C N Madu; K Mathisson; M Mayers
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

5.  Brimonidine tartrate-eudragit long-acting nanoparticles: formulation, optimization, in vitro and in vivo evaluation.

Authors:  Prakash Bhagav; Hariom Upadhyay; Sajeev Chandran
Journal:  AAPS PharmSciTech       Date:  2011-08-31       Impact factor: 3.246

6.  Preparation and characterization of eudragit retard nanosuspensions for the ocular delivery of cloricromene.

Authors:  Rosario Pignatello; Nadia Ricupero; Claudio Bucolo; Francesco Maugeri; Adriana Maltese; Giovanni Puglisi
Journal:  AAPS PharmSciTech       Date:  2006-03-24       Impact factor: 3.246

7.  In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride.

Authors:  S Miyazaki; S Suzuki; N Kawasaki; K Endo; A Takahashi; D Attwood
Journal:  Int J Pharm       Date:  2001-10-23       Impact factor: 5.875

8.  Design of a new multiparticulate system for potential site-specific and controlled drug delivery to the colonic region.

Authors:  M Rodríguez; J L Vila-Jato; D Torres
Journal:  J Control Release       Date:  1998-10-30       Impact factor: 9.776

9.  Sucrose stearate-based proniosome-derived niosomes for the nebulisable delivery of cromolyn sodium.

Authors:  A Abd-Elbary; H M El-laithy; M I Tadros
Journal:  Int J Pharm       Date:  2008-02-07       Impact factor: 5.875

10.  Carrageenan-gelatin mucoadhesive systems for ion-exchange based ophthalmic delivery: in vitro and preliminary in vivo studies.

Authors:  Maria Cristina Bonferoni; Patrizia Chetoni; Paolo Giunchedi; Silvia Rossi; Franca Ferrari; Susi Burgalassi; Carla Caramella
Journal:  Eur J Pharm Biopharm       Date:  2004-05       Impact factor: 5.571

View more
  3 in total

1.  Development of Solvent-Free Co-Ground Method to Produce Terbinafine Hydrochloride Cyclodextrin Binary Systems; Structural and In Vitro Characterizations.

Authors:  Balázs Attila Kondoros; Orsolya Jójárt-Laczkovich; Ottó Berkesi; Piroska Szabó-Révész; Ildikó Csóka; Rita Ambrus; Zoltán Aigner
Journal:  Pharmaceutics       Date:  2022-03-30       Impact factor: 6.525

2.  Enhancement of the Oral Bioavailability of Fexofenadine Hydrochloride via Cremophor(®) El-Based Liquisolid Tablets.

Authors:  Soad Ali Yehia; Mohamed Shafik El-Ridi; Mina Ibrahim Tadros; Nolwa Gamal El-Sherif
Journal:  Adv Pharm Bull       Date:  2015-11-30

3.  Nanoparticle formulation by Büchi B-90 Nano Spray Dryer for oral mucoadhesion.

Authors:  Sree N Harsha; Bander E Aldhubiab; Anroop B Nair; Ibrahim Abdulrahman Alhaider; Mahesh Attimarad; Katharigatta N Venugopala; Saminathan Srinivasan; Nagesh Gangadhar; Afzal Haq Asif
Journal:  Drug Des Devel Ther       Date:  2015-01-23       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.